Chemoresistance and cancer-related inflammation: Two hallmarks of cancer connected by an atypical link, PKCζ

Frontiers in Oncology

Volumn 3 SEP, Issue , 2013, Pages

  Rimessi, Alessandro ^a   Patergnani, Simone ^a   Ioannidi, Elli ^a   Pinton, Paolo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Apoptosis; Atypical PKC; Cancer; Chemoresistance; Inflammation; Nucleus; PKC

Indexed keywords

CASPASE 9; CERAMIDE; CYCLIN D; DAUNORUBICIN; DOXORUBICIN; I KAPPA B ALPHA; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; ISOPROTEIN; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOGLYCERATE DEHYDROGENASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE C EPSILON; PROTEIN P53; PROTEIN P62; RAF PROTEIN; REACTIVE OXYGEN METABOLITE; RITUXIMAB; SPHINGOMYELIN; STAT3 PROTEIN; STAT6 PROTEIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

APOPTOSIS; CANCER GROWTH; CELL CYCLE PROGRESSION; CHEMOSENSITIZATION; CHEMOTHERAPY; GENETIC TRANSCRIPTION; HUMAN; INFLAMMATION; NEOPLASM; NONHUMAN; NUCLEAR EXPORT SIGNAL; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84891065770     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00232     Document Type: Short Survey

References (80)

1. Bononi A, Agnoletto C, De Marchi E, Marchi S, Patergnani S, Bonora M, et al. Protein kinases and phosphatases in the control of cell fate. Enzyme Res (2011) 2011:329098. doi:10.4061/2011/329098
2. Giorgi C, Agnoletto C, Baldini C, Bononi A, Bonora M, Marchi S, et al. Redox control of protein kinase C: cell-and disease-specific aspects. Antioxid Redox Signal (2010) 13(7):1051-85. doi:10.1089/ars.2009.2825
3. Rosse C, Linch M, Kermorgant S, Cameron AJ, Boeckeler K, Parker PJ. PKC and the control of localized signal dynamics. Nat Rev (2010) 11(2):103-12. doi:10.1038/nrm2847
4. Ono Y, Fujii T, Ogita K, Kikkawa U, Igarashi K, Nishizuka Y. Protein kinase C zeta subspecies from rat brain: its structure, expression, and properties. Proc Natl Acad Sci U S A (1989) 86(9):3099-103. doi:10.1073/pnas.86.9.3099
5. Nakanishi H, Brewer KA, Exton JH. Activation of the zeta isozyme of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate. J Mol Biochem (1993) 268(1):13-6.
6. Limatola C, Schaap D, Moolenaar WH, van Blitterswijk WJ. Phosphatidic acid activation of protein kinase C-zeta overexpressed in COS cells: comparison with other protein kinase C isotypes and other acidic lipids. Biochem J (1994) 304(Pt 3):1001-8.
7. Muller G, Ayoub M, Storz P, Rennecke J, Fabbro D, Pfizenmaier K. PKC zeta is a molecular switch in signal transduction of TNF-alpha, bifunctionally regulated by ceramide and arachidonic acid. EMBO J (1995) 14(9):1961-9.
8. Rimessi A, Zecchini E, Siviero R, Giorgi C, Leo S, Rizzuto R, et al. The selective inhibition of nuclear PKCzeta restores the effectiveness of chemotherapeutic agents in chemoresistant cells. Cell Cycle (2012) 11(5):1040-8. doi:10.4161/cc.11.5.19520
9. Palmer RM, Nieto RM, Lobley GE, Da Silva P, Thom A, Thompson MG. Translocation of protein kinase C isoforms in rat muscle in response to fasting and refeeding. Br J Nutr (1999) 81(2):153-7.
10. Hirai T, Chida K. Protein kinase Czeta (PKCzeta): activation mechanisms and cellular functions. J Biochem (2003) 133(1):1-7. doi:10.1093/jb/mvg017
11. Rimessi A, Rizzuto R, Pinton P. Differential recruitment of PKC isoforms in HeLa cells during redox stress. Cell Stress Chaperones (2007) 12(4):291-8. doi:10.1379/CSC-211.1
12. Cross CE, Halliwell B, Borish ET, Pryor WA, Ames BN, Saul RL, et al. Oxygen radicals and human disease. Ann Intern Med (1987) 107(4):526-45. doi:10.7326/0003-4819-107-4-526
13. Cui X. Reactive oxygen species: the achilles' heel of cancer cells? Antioxid Redox Signal (2012) 16(11):1212-4. doi:10.1089/ars.2012.4532
14. Lee DJ, Kang SW. Reactive oxygen species and tumor metastasis. Mol Cells (2013) 35(2):93-8. doi:10.1007/s10059-013-0034-9
15. Marchi S, Giorgi C, Suski JM, Agnoletto C, Bononi A, Bonora M, et al. Mitochondria-ros crosstalk in the control of cell death and aging. J Signal Transduct (2012) 2012:329635. doi:10.1155/2012/329635
16. O'Brian CA, Ward NE. Biology of the protein kinase C family. Cancer Metastasis Rev (1989) 8(3):199-214. doi:10.1007/BF00047337
17. Urtreger AJ, Kazanietz MG, Bal de Kier Joffe ED. Contribution of individual PKC isoforms to breast cancer progression. IUBMB Life (2012) 64(1):18-26. doi:10.1002/iub.574
18. Ponting CP, Ito T, Moscat J, Diaz-Meco MT, Inagaki F, Sumimoto H. OPR PC and AID: all in the PB1 family. Trends Biochem Sci (2002) 27(1):10. doi:10.1016/S0968-0004(01)02006-0
19. Nigg EA. Nucleocytoplasmic transport: signals, mechanisms and regulation. Nature (1997) 386(6627):779-87. doi:10.1038/386779a0
20. Ossareh-Nazari B, Bachelerie F, Dargemont C. Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science (1997) 278(5335):141-4. doi:10.1126/science.278.5335.141
21. Murray NR, Jamieson L, Yu W, Zhang J, Gökmen-Polar Y, Sier D, et al. Protein kinase Ciota is required for Ras transformation and colon carcinogenesis in vivo. J Cell Biol (2004) 164(6):797-802. doi:10.1083/jcb.200311011
22. Jin Z, Xin M, Deng X. Survival function of protein kinase C{iota} as a novel nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-activated bad kinase. J Biol Chem (2005) 280(16):16045-52. doi:10.1074/jbc.M413488200
23. Fields AP, Regala RP. Protein kinase C iota: human oncogene, prognostic marker and therapeutic target. Pharmacol Res (2007) 55(6):487-97. doi:10.1016/j.phrs.2007.04.015
24. Diaz-Meco MT, Lozano J, Municio MM, Berra E, Frutos S, Sanz L, et al. Evidence for the in vitro and in vivo interaction of Ras with protein kinase C zeta. J Biol Chem (1994) 269(50):31706-10.
25. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science (2007) 318(5853):1108-13. doi:10.1126/science.1145720
26. Galvez AS, Duran A, Linares JF, Pathrose P, Castilla EA, Abu-Baker S, et al. Protein kinase Czeta represses the interleukin-6 promoter and impairs tumorigenesis in vivo. Mol Cell Biol (2009) 29(1):104-15. doi:10.1128/MCB.01294-08
27. Luna-Ulloa LB, Hernandez-Maqueda JG, Santoyo-Ramos P, Castaneda-Patlan MC, Robles-Flores M. Protein kinase C zeta is a positive modulator of canonical Wnt signaling pathway in tumoral colon cell lines. Carcinogenesis (2011) 32(11):1615-24. doi:10.1093/carcin/bgr190
28. Cornford P, Evans J, Dodson A, Parsons K, Woolfenden A, Neoptolemos J, et al. Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am J Pathol (1999) 154(1):137-44. doi:10.1016/S0002-9440(10)65260-1
29. Yao S, Bee A, Brewer D, Dodson A, Beesley C, Ke Y, et al. PRKC-zeta expression promotes the aggressive phenotype of human prostate cancer cells and is a novel target for therapeutic intervention. Genes Cancer (2010) 1(5):444-64. doi:10.1177/1947601910376079
30. Berra E, Diaz-Meco MT, Dominguez I, Municio MM, Sanz L, Lozano J, et al. Protein kinase C zeta isoform is critical for mitogenic signal transduction. Cell (1993) 74(3):555-63. doi:10.1016/0092-8674(93)80056-K
31. Laudanna C, Sorio C, Tecchio C, Butcher EC, Bonora A, Bassi C, et al. Motility analysis of pancreatic adenocarcinoma cells reveals a role for the atypical zeta isoform of protein kinase C in cancer cell movement. Lab Invest (2003) 83(8):1155-63. doi:10.1097/01.LAB.0000081390.92179.F3
32. Sun R, Gao P, Chen L, Ma D, Wang J, Oppenheim JJ, et al. Protein kinase C zeta is required for epidermal growth factor-induced chemotaxis of human breast cancer cells. Cancer Res (2005) 65(4):1433-41. doi:10.1158/0008-5472.CAN-04-1163
33. Kim JY, Valencia T, Abu-Baker S, Linares J, Lee SJ, Yajima T, et al. c-Myc phosphorylation by PKCzeta represses prostate tumorigenesis. Proc Natl Acad Sci U S A (2013) 110(16):6418-23. doi:10.1073/pnas.1221799110
34. Ma L, Tao Y, Duran A, Llado V, Galvez A, Barger JF, et al. Control of nutrient stress-induced metabolic reprogramming by PKCzeta in tumorigenesis. Cell (2013) 152(3):599-611. doi:10.1016/j.cell.2012.12.028
35. Mao M, Fang X, Lu Y, Lapushin R, Bast RC Jr, Mills GB. Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells. Biochem J (2000) 352(Pt 2):475-82. doi:10.1042/0264-6021:3520475
36. Mustafi R, Cerda S, Chumsangsri A, Fichera A, Bissonnette M. Protein kinase-zeta inhibits collagen I-dependent and anchorage-independent growth and enhances apoptosis of human Caco-2 cells. Mol Cancer Res (2006) 4(9):683-94. doi:10.1158/1541-7786.MCR-06-0057
37. Mas VM, Hernandez H, Plo I, Bezombes C, Maestre N, Quillet-Mary A, et al. Protein kinase Czeta mediated Raf-1/extracellular-regulated kinase activation by daunorubicin. Blood (2003) 101(4):1543-50. doi:10.1182/blood-2002-05-1585
38. Bezombes C, de Thonel A, Apostolou A, Louat T, Jaffrézou JP, Laurent G, et al. Overexpression of protein kinase Czeta confers protection against antileukemic drugs by inhibiting the redox-dependent sphingomyelinase activation. Mol Pharmacol (2002) 62(6):1446-55. doi:10.1124/mol.62.6.1446
39. Leseux L, Laurent G, Laurent C, Rigo M, Blanc A, Olive D, et al. PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood (2008) 111(1):285-91. doi:10.1182/blood-2007-04-085092
40. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res (2001) 7(3):709-23.
41. Vega MI, Jazirehi AR, Huerta-Yepez S, Bonavida B. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J Immunol (2005) 175(4):2174-83.
42. Fang J, Seki T, Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev (2009) 61(4):290-302. doi:10.1016/j.addr.2009.02.005
43. Khandrika L, Kumar B, Koul S, Maroni P, Koul HK. Oxidative stress in prostate cancer. Cancer Lett (2009) 282(2):125-36. doi:10.1016/j.canlet.2008.12.011
44. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 49(11):1603-16. doi:10.1016/j.freeradbiomed.2010.09.006
45. Visconti R, Grieco D. New insights on oxidative stress in cancer. Curr Opin Drug Discov Devel (2009) 12(2):240-5.
46. Pinton P, Rimessi A, Marchi S, Orsini F, Migliaccio E, Giorgio M, et al. Protein kinase C beta and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc. Science (2007) 315(5812):659-63. doi:10.1126/science.1135380
47. Brady SC, Allan LA, Clarke PR. Regulation of caspase 9 through phosphorylation by protein kinase C zeta in response to hyperosmotic stress. Mol Cell Biol (2005) 25(23):10543-55. doi:10.1128/MCB.25.23.10543-10555.2005
48. Yao H, Hwang JW, Moscat J, Diaz-Meco MT, Leitges M, Kishore N, et al. Protein kinase C zeta mediates cigarette smoke/aldehyde-and lipopolysaccharide-induced lung inflammation and histone modifications. J Biol Chem (2010) 285(8):5405-16. doi:10.1074/jbc.M109.041418
49. Borst P, Jonkers J, Rottenberg S. What makes tumors multidrug resistant? Cell Cycle (2007) 6(22):2782-7. doi:10.4161/cc.6.22.4936
50. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell (2002) 109(3):335-46. doi:10.1016/S0092-8674(02)00734-1
51. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov (2006) 5(3):219-34. doi:10.1038/nrd1984
52. Voorzanger-Rousselot N, Alberti L, Blay JY. CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways. BMC Cancer (2006) 6:75. doi:10.1186/1471-2407-6-75
53. de Visser KE, Jonkers J. Towards understanding the role of cancer-associated inflammation in chemoresistance. Curr Pharm Des (2009) 15(16):1844-53. doi:10.2174/138161209788453239
54. Ahn KS, Sethi G, Aggarwal BB. Nuclear factor-kappa B: from clone to clinic. Curr Mol Med (2007) 7(7):619-37. doi:10.2174/156652407782564363
55. Raju U, Gumin GJ, Noel F, Tofilon PJ. IkappaBalpha degradation is not a requirement for the X-ray-induced activation of nuclear factor kappaB in normal rat astrocytes and human brain tumour cells. Int J Radiat Biol (1998) 74(5):617-24. doi:10.1080/095530098141195
56. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J Biol Chem (1999) 274(39):27339-42. doi:10.1074/jbc.274.39.27339
57. Lallena MJ, Diaz-Meco MT, Bren G, Paya CV, Moscat J. Activation of IkappaB kinase beta by protein kinase C isoforms. Mol Cell Biol (1999) 19(3):2180-8.
58. Leitges M, Sanz L, Martin P, Duran A, Braun U, García JF, et al. Targeted disruption of the zetaPKC gene results in the impairment of the NF-kappaB pathway. Mol Cell (2001) 8(4):771-80. doi:10.1016/S1097-2765(01)00361-6
59. Bourbon NA, Yun J, Kester M. Ceramide directly activates protein kinase C zeta to regulate a stress-activated protein kinase signaling complex. J Biol Chem (2000) 275(45):35617-23. doi:10.1074/jbc.M007346200
60. Duran A, Linares JF, Galvez AS, Wikenheiser K, Flores JM, Diaz-Meco MT, et al. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell (2008) 13(4):343-54. doi:10.1016/j.ccr.2008.02.001
61. Moscat J, Diaz-Meco MT, Albert A, Campuzano S. Cell signaling and function organized by PB1 domain interactions. Mol Cell (2006) 23(5):631-40. doi:10.1016/j.molcel.2006.08.002
62. Knupfer H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat (2007) 102(2):129-35. doi:10.1007/s10549-006-9328-3
63. Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell (2009) 15(2):79-80. doi:10.1016/j.ccr.2009.01.009
64. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 7(3):211-7. doi:10.1016/j.ccr.2005.02.013
65. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 4(1):71-8. doi:10.1038/nrc1256
66. Grivennikov S, Karin M. Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell (2008) 13(1):7-9. doi:10.1016/j.ccr.2007.12.020
67. Duran A, Diaz-Meco MT, Moscat J. Essential role of RelA Ser311 phosphorylation by zetaPKC in NF-kappaB transcriptional activation. EMBO J (2003) 22(15):3910-8. doi:10.1093/emboj/cdg370
68. Goto M, Katayama KI, Shirakawa F, Tanaka I. Involvement of NF-kappaB p50/p65 heterodimer in activation of the human pro-interleukin-1beta gene at two subregions of the upstream enhancer element. Cytokine (1999) 11(1):16-28. doi:10.1006/cyto.1998.0390
69. Thomas JA, Allen JL, Tsen M, Dubnicoff T, Danao J, Liao XC, et al. Impaired cytokine signaling in mice lacking the IL-1 receptor-associated kinase. J Immunol (1999) 163(2):978-84.
70. Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol (2009) 1(5):a000141. doi:10.1101/cshperspect.a000141
71. Braunstein S, Formenti SC, Schneider RJ. Acquisition of stable inducible up-regulation of nuclear factor-kappaB by tumor necrosis factor exposure confers increased radiation resistance without increased transformation in breast cancer cells. Mol Cancer Res (2008) 6(1):78-88. doi:10.1158/1541-7786.MCR-07-0339
72. Takebayashi T, Higashi H, Sudo H, Ozawa H, Suzuki E, Shirado O, et al. NF-kappa B-dependent induction of cyclin D1 by retinoblastoma protein (pRB) family proteins and tumor-derived pRB mutants. J Biol Chem (2003) 278(17):14897-905. doi:10.1074/jbc.M210849200
73. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol (2003) 171(1):88-95.
74. Cuní S, Pérez-Aciego P, Pérez-Chacón G, Vargas JA, Sánchez A, Martín-Saavedra FM, et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia (2004) 18(8):1391-400. doi:10.1038/sj.leu.2403398
75. Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, et al. Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 23(5):634-46. doi:10.1016/j.ccr.2013.03.022
76. Levy D, Kuo AJ, Chang Y, Schaefer U, Kitson C, Cheung P, et al. Lysine methylation of the NF-kappaB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-kappaB signaling. Nat Immunol (2011) 12(1):29-36. doi:10.1038/ni.1968
77. Martin P, Duran A, Minguet S, Gaspar ML, Diaz-Meco MT, Rennert P, et al. Role of zeta PKC in B-cell signaling and function. EMBO J (2002) 21(15):4049-57. doi:10.1093/emboj/cdf407
78. Martin P, Villares R, Rodriguez-Mascarenhas S, Zaballos A, Leitges M, Kovac J, et al. Control of T helper 2 cell function and allergic airway inflammation by PKCzeta. Proc Natl Acad Sci U S A (2005) 102(28):9866-71. doi:10.1073/pnas.0501202102
79. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell (2002) 109(Suppl):S81-96. doi:10.1016/S0092-8674(02)00703-1
80. Gonda TA, Tu S, Wang TC. Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle (2009) 8(13):2005-13. doi:10.4161/cc.8.13.8985